Effect of recombinant human interleukin 2 (rIL-2) on normal peripheral blood B cells and B lymphoblastoid cell lines.
The role of interleukin 2 (IL-2) for growth and differentiation of normal and malignant B cells still remains controversial. We assessed normal peripheral blood B cells and cell lines derived from patients with B non-Hodgkin's lymphomas (NHLs) with respect to their responsiveness to recombinant human IL-2 (rIL-2). The NHL cell lines used in our experiments expressed the Tac antigen (CD25)--a compound of the IL-2 receptor (IL-2R)--in a percentage ranging from 28 to 57%. As measured in a [3H]thymidine uptake assay, the normal peripheral blood B cells demonstrated a dose-dependent proliferative response to rIL-2, whereas the NHL cells did not show any responsiveness to rIL-2. In a clonogenic culture assay we evaluated the colony formation of the NHL cells and found a decrease of 28 to 41% on average in the presence of rIL-2 (10-50 U/ml). This moderate inhibitory effect on the clonal growth of the NHL cells was not due to a differentiation inducing effect of rIL-2, as studied by measuring the Ig production under increasing doses of rIL-2 (1 to 100 U/ml). Thus, malignant NHL B cells may express the CD25 compound of the IL-2 receptor on their surface, demonstrating a different functional responsiveness to rIL-2 compared to normal peripheral blood B cells.
Haas
R
R
Department of Internal Medicine V, University of Heidelberg, F.R.G.
Hohaus
S
S
Kiesel
S
S
Ogniben
E
E
Ehrhardt
R
R
Hunstein
W
W
D001402:B-Lymphocytes / Q000166:cytology / Q000187:drug effects*; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D005455:Fluorescent Antibody Technique; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000187:drug effects; D007376:Interleukin-2 / Q000494:pharmacology*; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology*; D011994:Recombinant Proteins; D014407:Tumor Cells, Cultured
D007074:Immunoglobulin G; D007376:Interleukin-2; D011994:Recombinant Proteins